

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hans Weiher, et al.
Application No. : 10/644,325 Confirmation No.: 6657
Filed : August 19, 2003
For : USE OF γ -GT INHIBITORS FOR THE TREATMENT
OF DEGENERATIVE DISEASES
Group Art Unit : 1623
Examiner : Not yet assigned

New York, New York 10020
January 21, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT**

Sir:


Transmitted herewith is an Information Disclosure Statement in the
above-identified application. This Statement is submitted:

- within three months of the application filing date;
- more than three months from the application
filing date but before the mailing date of the first
Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement
requires no fee. However, if for any reason a fee is due, the Director is hereby
authorized to charge payment of any fees required in connection with this Information

Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.


Respectfully submitted,


Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
R. Minako Pazdera (Reg. No. 46,984)
Agents for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

January 21, 2004

Lillian Garcia


Signature of Person Signing



VOS-44 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned
Group : 1623
Applicant : Hans Weiher, et al.
Application No. : 10/644,325 Confirmation No. 6657
Filed : August 19, 2003
For : USE OF γ -GT INHIBITORS FOR THE TREATMENT OF DEGENERATIVE DISEASES

New York, New York 10020
January 21, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their representatives, make of record the following documents,¹ copies of which are submitted herewith:

United States Patent Documents

<u>Patent No.</u>	<u>Name</u>	<u>Issued</u>
4,758,551	Meister et al.	July 19, 1988

¹ For the Examiner's convenience, applicants have enclosed a completed Form PTO-1449, listing these documents.

Articles

Evans, P., Halliwell, B. "Free Radicals and Hearing: Cause, Consequence, and Criteria," *Annals New York Academy of Sciences*, 884:19-40 (1999).

Hanigan, M. H. et al. "Cisplatin nephrotoxicity: Inhibition of γ -Glutamyl Transpeptidase Blocks the Nephrotoxicity of Cisplatin without Reducing Platinum Concentrations in the Kidney," *American Journal of Obstetrics and Gynecology*, 175:270-274 (1996).

Hanigan, M. H. et al. "Expression of Gamma-Glutamyl Transpeptidase in Stage III and IV Ovarian Surface Epithelial Carcinomas Does Not Alter Response to Primary Cisplatin-Based Chemotherapy," *Database Biosis* (1998).

Hanigan, M. H. et al. "Human Germ Cell Tumours: Expression of Gamma-Glutamyl Transpeptidase and Sensitivity to Cisplatin," *British Journal of Cancer* 81:75-79 (1999).

Isao, N. et al. "Attenuation of Aminoglycoside Ototoxicity by Glutathione," *Database Biosis Online!* (1996).

Kil, J. et al. "Localization of Gamma-Glutamyl Transpeptidase in the Chick Inner Ear Sensory Epithelia," *Society for Neuroscience*, 22:1621 (1996).

Lopez-Gonzalez, M. A. et al. "Ototoxicity Caused by Cisplatin is Ameliorated by Melatonin and Other Antioxidants", *Journal of Pineal Research*, 28:73-80 (2000).

Townsend, D. M. et al. "In Vivo Metabolism of Cisplatin to a Nephrotoxin by Gamma-Glutamyl Transpeptidase and Beta-Lyase." *Proceedings of the American Association for Cancer Research Annual*, 41:266 (2000).

Applicants respectfully request that these documents be (1) considered by the Examiner prior to issuance of any patent from this application; and (2) printed on any patent that may issue from this application. Applicants also request that a

copy of enclosed Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

Respectfully submitted,


Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants

Shawn-Marie Mayrand (Reg. No. 48,986)

R. Minako Pazdera (Reg. No. 46,984)

Agents for Applicants

FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas


New York, New York 10020-1105


Tel.: (212) 596-9000

Fax: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

January 21, 2004
Lillian Garcia


Signature of Person Signing


**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS**
**ATTY. DOCKET NO.
VOS-44 CON**
**APPLICATION NO.
10/644,325**
APPLICANTS

Hans Weiher, et al.

**CONFIRMATION NO.
6657**
FILING DATE

August 19, 2003

**GROUP
1623**
U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,758,551	7/19/88	Meister et al.	514	18	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Evans, P., Halliwell, B. "Free Radicals and Hearing: Cause, Consequence, and Criteria," <i>Annals New York Academy of Sciences</i> , 884:19-40 (1999)
	Hanigan, M. H. et al. "Cisplatin nephrotoxicity: Inhibition of γ -Glutamyl Transpeptidase Blocks the Nephrotoxicity of Cisplatin without Reducing Platinum Concentrations in the Kidney," <i>American Journal of Obstetrics and Gynecology</i> , 175:270-274 (1996)
	Hanigan, M. H. et al. "Expression of Gamma-Glutamyl Transpeptidase in Stage III and IV Ovarian Surface Epithelial Carcinomas Does Not Alter Response to Primary Cisplatin-Based Chemotherapy," <i>Database Biosis</i> (1998)
	Hanigan, M. H. et al. "Human Germ Cell Tumours: Expression of Gamma-Glutamyl Transpeptidase and Sensitivity to Cisplatin," <i>British Journal of Cancer</i> , 81:75-79 (1999)
	Isao, N. et al. "Attenuation of Aminoglycoside Ototoxicity by Glutathione," <i>Database Biosis Online!</i> (1996)
	Kil, J. et al. "Localization of Gamma-Glutamyl Transpeptidase in the Chick Inner Ear Sensory Epithelia," <i>Society for Neuroscience</i> , 22:1621 (1996)
	Lopez-Gonzalez, M. A. et al. "Ototoxicity Caused by Cisplatin is Ameliorated by Melatonin and Other Antioxidants," <i>Journal of Pineal Research</i> , 28:73-80 (2000)
	Townsend, D. M. et al. "In Vivo Metabolism of Cisplatin to a Nephrotoxin by Gamma-Glutamyl Transpeptidase and Beta-Lyase," <i>Proceedings of the American Association for Cancer Research Annual</i> , 41:266 (2000)

EXAMINER
DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.